Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this single-center study is to explore the efficacy, safety, tolerability and
pharmacokinetics/pharmacodynamics of recombinant human C1 inhibitor in the treatment of acute
attacks in patients with hereditary angioedema.
Phase:
Phase 2
Details
Lead Sponsor:
Pharming Technologies B.V.
Treatments:
Complement C1 Inactivator Proteins Complement C1 Inhibitor Protein